1. Home
  2. VRTX vs DE Comparison

VRTX vs DE Comparison

Compare VRTX & DE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • DE
  • Stock Information
  • Founded
  • VRTX 1989
  • DE 1837
  • Country
  • VRTX United States
  • DE United States
  • Employees
  • VRTX N/A
  • DE 83000
  • Industry
  • VRTX EDP Services
  • DE Industrial Machinery/Components
  • Sector
  • VRTX Technology
  • DE Industrials
  • Exchange
  • VRTX Nasdaq
  • DE Nasdaq
  • Market Cap
  • VRTX 128.5B
  • DE 110.7B
  • IPO Year
  • VRTX 1991
  • DE N/A
  • Fundamental
  • Price
  • VRTX $467.01
  • DE $404.35
  • Analyst Decision
  • VRTX Buy
  • DE Buy
  • Analyst Count
  • VRTX 29
  • DE 17
  • Target Price
  • VRTX $513.58
  • DE $421.63
  • AVG Volume (30 Days)
  • VRTX 1.2M
  • DE 1.0M
  • Earning Date
  • VRTX 11-04-2024
  • DE 11-21-2024
  • Dividend Yield
  • VRTX N/A
  • DE 1.45%
  • EPS Growth
  • VRTX N/A
  • DE N/A
  • EPS
  • VRTX N/A
  • DE 29.34
  • Revenue
  • VRTX $10,625,800,000.00
  • DE $55,955,000,000.00
  • Revenue This Year
  • VRTX $12.20
  • DE N/A
  • Revenue Next Year
  • VRTX $8.31
  • DE N/A
  • P/E Ratio
  • VRTX N/A
  • DE $13.78
  • Revenue Growth
  • VRTX 10.06
  • DE N/A
  • 52 Week Low
  • VRTX $346.29
  • DE $340.20
  • 52 Week High
  • VRTX $519.88
  • DE $420.47
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 42.88
  • DE 51.98
  • Support Level
  • VRTX $489.02
  • DE $387.03
  • Resistance Level
  • VRTX $519.88
  • DE $415.50
  • Average True Range (ATR)
  • VRTX 14.86
  • DE 8.52
  • MACD
  • VRTX -2.67
  • DE -0.57
  • Stochastic Oscillator
  • VRTX 14.49
  • DE 60.84

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About DE Deere & Company

Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry in their green and yellow livery. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.

Share on Social Networks: